Compare FPH & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FPH | CLLS |
|---|---|---|
| Founded | 2009 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 383.2M | 394.4M |
| IPO Year | 2013 | 2014 |
| Metric | FPH | CLLS |
|---|---|---|
| Price | $5.16 | $3.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.33 |
| AVG Volume (30 Days) | ★ 179.5K | 16.7K |
| Earning Date | 04-23-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $110,020,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $0.98 |
| P/E Ratio | $11.40 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.60 | $2.35 |
| 52 Week High | $6.64 | $5.48 |
| Indicator | FPH | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 49.95 | 56.29 |
| Support Level | $4.89 | $2.94 |
| Resistance Level | $5.37 | $3.40 |
| Average True Range (ATR) | 0.13 | 0.17 |
| MACD | -0.01 | 0.06 |
| Stochastic Oscillator | 30.65 | 75.22 |
Five Point Holdings LLC is an owner and developer of mixed-use, master-planned communities in California. It is engaged in developing new communities that, in addition to homesites, include commercial, retail, educational, and recreational elements, as well as civic areas, parks, and open spaces. Its four reportable segments are Valencia, San Francisco, Great Park, and Hearthstone. It derives the majority of revenue from the Great Park segment, which includes Great Park Neighborhoods being developed adjacent to and around the Orange County Great Park, a metropolitan park under construction in Orange County, California.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.